Delaware Judge Axes Novartis Patent On Heart Failure Drug

By Ryan Davis · July 7, 2023, 9:01 PM EDT

A Delaware federal judge ruled Friday that a patent covering Entresto, a blockbuster heart failure drug made by Novartis, is invalid for lacking an adequate written description, handing a win to...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

In re: Entresto (Sacubitril/Valsartan) Patent Litigation

Case Number

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

March 27, 2020

Recent Articles By Ryan

June 21, 2024
Drugmakers Decline To Drop Patent Listings After FTC Letters
April 04, 2024
Microsoft Unit Gets Fed. Circ. Alice Win On Imaging Patents
March 06, 2024
CBP Details Apple Watch Redesign OK In Masimo Patent Row
March 04, 2024
WTO Conference Ends Without COVID IP Waiver Expansion
January 17, 2024
Apple Drops Blood Oxygen Tech From New Watches After Ban
January 15, 2024
Apple Cleared To Avoid Import Ban With Redesigned Watch
December 28, 2023
Apple Watch Import Ban Put On Hold By Fed. Circ.
December 26, 2023
White House Won't Veto ITC Apple Watch Import Ban
December 20, 2023
ITC Rejects Apple's Bid To Put Apple Watch Ban On Hold
December 06, 2023
Fed. Circ. Wrestles With Apple Bid To Ax More Masimo Patents